Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,554 questions in 140 reviews · Heart
current versionsNo studies 272 · 17.5%Ungraded 44 · 2.8%Very low 329 · 21.2%Low 464 · 29.9%Moderate 319 · 20.5%High 126 · 8.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Natriuretic peptide‐guided treatment vs standard care Ventricular dysfunction (as defined by trialists) · patients without heart failure Natriuretic peptide‐guided treatment for the prevention of cardiovascular events in patients without heart… (2019) · Cochrane | RR 0.61 [0.41, 0.91] | 1 study · 1374 participants | High |
Natriuretic peptide‐guided treatment vs standard care Change in NP level at the end of · patients without heart failure Natriuretic peptide‐guided treatment for the prevention of cardiovascular events in patients without heart… (2019) · Cochrane | no estimate extracted | 1 study · 1374 participants | Moderate |
Intervention NR APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 2 studies · 4930 participants | Moderate |
Intervention NR RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 2 studies · 1546 participants | Very low |
Intervention NR RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 1 study · 1399 participants | Low |
Intervention NR DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 1 study · 1962 participants | Low |
Intervention NR DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 1 study · 1527 participants | Low |
Intervention NR APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 2 studies · 4865 participants | Moderate |
Intervention NR RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 2 studies · 1546 participants | Very low |
Intervention NR RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 1 study · 1403 participants | Low |
Intervention NR DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 1 study · 1962 participants | Moderate |
Intervention NR DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 1 study · 1527 participants | Low |
Intervention NR APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 2 studies · 4930 participants | Moderate |
Intervention NR RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 2 studies · 1542 participants | Very low |
Intervention NR RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 1 study · 1393 participants | Low |
Intervention NR RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 1 study · 1403 participants | Low |
Intervention NR DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 1 study · 1962 participants | Low |
Intervention NR DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 1 study · 1527 participants | Low |
Intervention NR APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 1 study · 4614 participants | Moderate |
Intervention NR RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 1 study · 1389 participants | Low |
Intervention NR RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 1 study · 1399 participants | Low |
Intervention NR DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 1 study · 1962 participants | Low |
Intervention NR DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 1 study · 1527 participants | Low |
Intervention NR RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 1 study · 1399 participants | Low |
Intervention NR APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 2 studies · 4930 participants | Moderate |
Intervention NR RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 2 studies · 1542 participants | Very low |
Intervention NR RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 1 study · 1399 participants | Low |
Intervention NR DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 1 study · 1962 participants | Low |
Intervention NR DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 1 study · 1527 participants | Low |
Intervention NR APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network… (2019) · Cochrane | no estimate extracted | 2 studies · 4930 participants | Low |
Transcatheter aortic valve implantation vs surgical aortic valve replacement Outcomes (up to 30 days' · adults with severe aortic stenosis who are at a low surgical risk. Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis… (2019) · Cochrane | no estimate extracted | NR | No studies |
Transcatheter aortic valve implantation vs surgical aortic valve replacement All‐cause mortality · adults with severe aortic stenosis who are at a low surgical risk. Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis… (2019) · Cochrane | RR 0.69 [0.33, 1.44] | 4 studies · 2818 participants | Moderate |
Transcatheter aortic valve implantation vs surgical aortic valve replacement Stroke · adults with severe aortic stenosis who are at a low surgical risk. Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis… (2019) · Cochrane | RR 0.73 [0.42, 1.25] | 4 studies · 2818 participants | Moderate |
Transcatheter aortic valve implantation vs surgical aortic valve replacement Rehospitalisation · adults with severe aortic stenosis who are at a low surgical risk. Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis… (2019) · Cochrane | RR 0.64 [0.39, 1.06] | 2 studies · 2468 participants | Low |
Transcatheter aortic valve implantation vs surgical aortic valve replacement Myocardial infarction · adults with severe aortic stenosis who are at a low surgical risk. Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis… (2019) · Cochrane | RR 0.82 [0.42, 1.58] | 3 studies · 2748 participants | Moderate |
Transcatheter aortic valve implantation vs surgical aortic valve replacement Cardiac death · adults with severe aortic stenosis who are at a low surgical risk. Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis… (2019) · Cochrane | RR 0.71 [0.32, 1.56] | 4 studies · 2818 participants | Moderate |
Transcatheter aortic valve implantation vs surgical aortic valve replacement Length of hospital stay · adults with severe aortic stenosis who are at a low surgical risk. Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis… (2019) · Cochrane | no estimate extracted | NR | Very low |
Transcatheter aortic valve implantation vs surgical aortic valve replacement Permanent pacemaker implantation · adults with severe aortic stenosis who are at a low surgical risk. Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis… (2019) · Cochrane | RR 3.65 [1.5, 8.87] | 3 studies · 2683 participants | Moderate |
Mechanical chest compressions vs manual chest compressions Survival to hospital discharge with good neurological function · patients with cardiac arrest Mechanical versus manual chest compressions for cardiac arrest (2018) · Cochrane | no estimate extracted | 3 studies · 7587 participants | Moderate |
Mechanical chest compressions vs manual chest compressions Survival to hospital discharge · patients with cardiac arrest Mechanical versus manual chest compressions for cardiac arrest (2018) · Cochrane | no estimate extracted | 7 studies · 8067 participants | Moderate |
Mechanical chest compressions vs manual chest compressions Return of spontaneous circulation · patients with cardiac arrest Mechanical versus manual chest compressions for cardiac arrest (2018) · Cochrane | no estimate extracted | 8 studies · 11771 participants | Low |
Mechanical chest compressions vs manual chest compressions Survival to hospital admission · patients with cardiac arrest Mechanical versus manual chest compressions for cardiac arrest (2018) · Cochrane | no estimate extracted | 4 studies · 7224 participants | Moderate |
Mechanical chest compressions vs manual chest compressions Sternal or rib fractures · patients with cardiac arrest Mechanical versus manual chest compressions for cardiac arrest (2018) · Cochrane | no estimate extracted | 7 studies · 7469 participants | Low |
Mechanical chest compressions vs manual chest compressions Haemothorax or pneumothorax · patients with cardiac arrest Mechanical versus manual chest compressions for cardiac arrest (2018) · Cochrane | no estimate extracted | 5 studies · 7316 participants | Low |
Mechanical chest compressions vs manual chest compressions Internal abdominal organ injury · patients with cardiac arrest Mechanical versus manual chest compressions for cardiac arrest (2018) · Cochrane | no estimate extracted | 5 studies · 7337 participants | Low |
Higher vs lower omega‐6: primary outcomes All‐cause mortality Study duration range 12‐96 months Omega‐6 dose range 1.5%‐24.5% E · adults with or without existing CVD Omega‐6 fats for the primary and secondary prevention of cardiovascular disease (2018) · Cochrane | RR 1 [0.88, 1.12] | 10 studies · 4506 participants | Low |
Higher vs lower omega‐6: additional key outcomes LDL Study duration range 12‐24 months Omega‐6 dose range 2.0%‐15.0% E · adults with or without existing CVD Omega‐6 fats for the primary and secondary prevention of cardiovascular disease (2018) · Cochrane | no estimate extracted | 2 studies · 244 participants | Low |
Higher vs lower omega‐6: additional key outcomes HDL Study duration range 12‐24 months Omega‐6 dose range 2.0%‐15.0% E · adults with or without existing CVD Omega‐6 fats for the primary and secondary prevention of cardiovascular disease (2018) · Cochrane | no estimate extracted | 4 studies · 1995 participants | Low |
Higher vs lower omega‐6: additional key outcomes Body weight (kg) Study duration range 12‐48 months Omega‐6 dose range 0.8%‐2.8% E · adults with or without existing CVD Omega‐6 fats for the primary and secondary prevention of cardiovascular disease (2018) · Cochrane | no estimate extracted | 4 studies · 358 participants | Very low |
Higher vs lower omega‐6: additional key outcomes BMI Study duration 51 months Omega‐6 dose 6.6% E · adults with or without existing CVD Omega‐6 fats for the primary and secondary prevention of cardiovascular disease (2018) · Cochrane | no estimate extracted | 1 study · 371 participants | Moderate |